In vitro results suggested that CD19 CAR could be detected on T cells at 30 h post-transfection, and the mean transfection rate was 3.8%; in vivo experiments indicated similar anti-leukemia activity compared with conventional LV transfection in vitro. This evidence concerns the gene CD19 and leukemia.